CONQUER CANCER®
THE ASCO FOUNDATION

2027 CONQUER CANCER CAREER DEVELOPMENT AWARD IN OVARIAN CANCER

REQUEST FOR PROPOSALS

Last updated: June 30, 2026

Application Deadline: January 28, 2027

Conquer Cancer®, the ASCO Foundation
2318 Mill Road, Suite 800
Alexandria, VA 22314
grants@conquer.org

Please visit asco.org/CDA for the most up-to-date version of the Request for Proposals.

About Conquer Cancer®, the ASCO Foundation

Conquer Cancer funds research for every cancer, every patient, everywhere. Since 1984, its Grants & Awards program has awarded more than $215 million through more than 10,500 grants and awards to improve cancer care and accelerate breakthroughs in clinical and translational oncology research. Conquer Cancer donors support vital programs needed to deliver the highest quality patient care and share a vision of a world where cancer is prevented or cured, and every survivor is healthy. For more information visit CONQUER.ORG.

Table of Contents

Purpose 3
Funding Available 3
Eligibility Criteria 3
Research Project Criteria 4
Peer Review of Applications 5
Key Dates 6
Application Changes 6
Award Notification 7
Application Procedures 7
1. Applicant Information (required). 8
2. Project Information (required). 8
3. Research Strategy (required). 10
4. Biostatistical Section (required). 11
5. Cited References (required). 12
6. Patient Impact Section (required). 12
7. Budget (required). 14
8. Project Timeline Form (required). 14
9. Resubmission Documentation (required for resubmissions only). 15
10. Personal Statement Form (required). 15
11. Applicant's Biosketch (required) 15
12. Mentor and Sponsor Recommendation (required). 16
13. Mentorship Plan (required). 18
14. Institutional Letter of Support from Department Chair or Dean (required). 18
15. Clinical Protocol (required). 19
16. Letter from Drug Company (optional). 19
17. Publications (optional). 19
18. Additional Supporting Documentation (optional). 20
19. Institution Approval (required). 20
20. Review and Submit (required) 21
Appendix A. Terms & Conditions 22
Appendix B. Helpful Tips for Using the Application Portal 29
Getting Started 29
Completing the Eligibility Quiz 29
Navigating the Application 29
Uploading a Document 30
Requesting a Recommendation 30
Receiving Notifications 31
Appendix C. Application Information Use and Sharing 31
Appendix D. Physician Payments Sunshine Act 32
Appendix E. Compliance with Applicable Legal Requirements (For Non-U.S. Institutions and Entities) 33

Purpose

The Conquer Cancer Career Development Award (CDA) in Ovarian Cancer provides funding to clinical investigators who have received their initial faculty appointment and are establishing an independent research career focused on ovarian cancer. This is a mentored award, and the research project is conducted under the guidance of an experienced mentor in the proposed research area. Applications in all areas of cancer research are accepted from U.S. and international applicants.

Funding Available

The total award amount is $200,000 payable in annual increments of $66,666 over three years. Conquer Cancer has funding for one CDA in Ovarian Cancer which will be awarded to the most meritorious application focused on ovarian cancer research.

Eligibility Criteria

Applicants must meet the following criteria:

- A physician (MD, DO, or international equivalent with explanation) working in any country.
- In the first to fourth year of a full-time primary faculty appointment in a clinical department at an academic medical institution at the time of grant submission. Faculty appointment may begin with the entry-level faculty position within the applicant's institution (i.e., Instructor/Lecturer, Assistant Professor, Assistant Member).
- Have a valid, active medical license in the country where the research will be conducted at the time of application.
- Have completed productive postdoctoral research and demonstrated the ability to undertake independent investigator-initiated clinical research in ovarian cancer.
- Be a current ASCO member or have submitted a membership application with the grant application. To apply for new membership, or to renew an existing membership, visit asco.org/membership.
- Able to commit at least 50% of their time for research (applies to total effort, not just the proposed CDA project) during the award period.
- Have a mentor from the sponsoring institution. If the mentor is not an ASCO member, a supporting letter from an ASCO member from the sponsoring institution must be included.
- Be up-to-date and in compliance with all requirements (e.g., progress reports, final reports, budget summaries, IRB approvals, etc.) of any past grants received from Conquer Cancer.
- Applicants with concurrent federal career development awards (e.g., K23, K08, or any other type of career development award), career development awards from private foundations, and institutional training grants (T32, KL2/K12 or equivalent) are eligible to apply provided there are no scientific and budgetary overlaps. *Note: Conquer Cancer must be informed when a CDA recipient receives other career development awards during the term of the CDA and reserves the right to determine that the CDA may not be held concurrent with other funding. Past recipients of training fellowships (e.g., Young Investigator Award or an F32 grant) are eligible to apply.*

- Applicants should not have been a Principal Investigator on any large project grants (e.g., R01 or international equivalent).

NOTE: While first year faculty may be eligible for both the Young Investigator Award (YIA) and the Career Development Award (CDA) programs, they are restricted to a single submission. Applicants must only submit one application to either the YIA or the CDA competition and may not submit to both programs simultaneously.

If there are questions regarding eligibility associated with previous and current grants received, applicants are encouraged to email grants@conquer.org for clarification.

Eligible applicants are allowed to hold only one active grant from Conquer Cancer at a time.

There are no citizenship or geographic requirements. However, by submitting an application, an applicant applying from an institution located in a country in which they are not a citizen or a permanent resident assures that the visa status will provide sufficient time to complete the project during the grant term at the institution from which they applied.

Conquer Cancer staff and the Conquer Cancer Grants Selection Committee reserve the right to evaluate and determine an applicant's eligibility based on the information and justifications provided in the application materials. **Applicants who are uncertain about their eligibility are encouraged to review the Eligibility section of the FAQ or contact grants@conquer.org for clarification. Please include your latest CV in your email so that Conquer Cancer can properly assess your background.**

Research Project Criteria

The CDA is intended to support proposals with a clinical research focus involving human subjects. ASCO's definition of clinical research is "hypothesis-driven research that employs measurements in whole patients or normal human subjects, in conjunction with laboratory measurements as appropriate, on the subjects of clinical biology, natural history, prevention, screening, diagnosis, therapy, or epidemiology of neoplastic disease" (*Journal of Clinical Oncology*, Vol. 14, No. 2, 1996 pp. 666-670). Proposals with a predominant focus on in vitro or animal studies (even if clinically relevant) are not allowed. Proposals can include epidemiologic and behavioral studies, quality of cancer care research, outcomes research and health services research. **Proposals must have clearly defined, measurable outcomes that demonstrate project feasibility. The project must have a realistic timeline for completion within the three-year grant term.**

CDA proposals must have a patient-oriented focus and ensure that the research reflects the needs of patients with cancer and must be developed with the participation of a patient advocate. Please refer to the Patient Impact Section of this Request for Proposals (RFP) for additional information about engaging a patient advocate in the CDA project. Please note that all proposals are reviewed by a patient advocate.

Peer Review of Applications

All Conquer Cancer research grant applications are carefully reviewed and evaluated by an independent Grants Selection Committee (Committee) using consistent criteria across all applications for each grant or award type. The Committee scores and ranks the applications, and the highest-scoring applications are funded.

In some circumstances, applications already approved to receive funding based on their high application scores may be matched with Conquer Cancer grants that have additional donor-specified criteria. However, all approved applications will receive Conquer Cancer research grants. In no case will an application not eligible for funding in the initial review process receive a Conquer Cancer research grant.

CDA applications are reviewed by the Committee using a multi-stage, confidential review process. Each application is assigned to at least two committee members who are scientific leaders in their areas of expertise to independently evaluate its scientific merit. Top ranking applications are then assigned to a biostatistician and a patient advocate to evaluate statistical rigor and incorporate the patient perspective. The highest-rated applications advance to the final review stage where the full Committee discuss their overall merits to determine the final award recipients.

CDA applications are evaluated and scored by the Committee based on the following criteria using the 1-9 NIH scoring scale.

Primary Criteria:

- Potential for the applicant to pursue an academic clinical oncology career (~35%)
    - Prior research experience and accomplishments of the applicant during research training
    - Potential favorable impact on career development of the applicant
- Strength of the hypothesis-driven proposal with a clinical research focus (~35%)
    - A focus on patient-oriented clinical investigation
    - Significance and originality of the proposed study and hypothesis
    - Appropriate and detailed statistical analysis plan
    - Appropriateness, feasibility, and adequacy of the proposed experimental design and methodology

Secondary Criteria:

- Strength of the mentor in supporting the applicant's proposal and in facilitating the applicant's career development (~20%)
    - Quality of the mentor and the plan for mentoring interactions with applicant
- Availability of institutional resources to support the applicant and proposed project (~10%)

Key Dates

Online Applications Open:	**July 1, 2026**
Full Applications Due:	**January 28, 2027 (11:59 PM ET)**
Post Submission Materials Deadline**:**	**February 18, 2027**
Notification Date:	**April 2027**
Award Term:	**July 1, 2027 – June 30, 2030**

Post Submission Materials Accepted **(Deadline: February 18, 2027)**
• Acceptance of publication since submission of the grant application • IRB approval • Clinical protocol *(required)* • If mentor left the institution: New mentor biosketch, letter of support, and updated mentorship plan *(required)* • Letter/proof of receipt of drug from a company or any additional letters of collaboration

NOTE: These documents are optional, unless otherwise indicated, but are highly encouraged to be provided for inclusion in the application review.

Application Changes

The applicant must notify Conquer Cancer **immediately** by sending an email to grants@conquer.org if any of the following conditions occur between application submission and the award notification period:

- Withdrawal of Application. Send an email containing the following details: the applicant's full name, the title of the submitted proposal, and the reason for withdrawing the application.
- Change of Institution Status or Position. The applicant has a career plan change, leaves their current position in the institution, or becomes unable to meet the eligibility requirements of this RFP. If the applicant is selected to receive a CDA, Conquer Cancer has the right in its sole discretion to withdraw the award.
- Mentor or Co-Mentor Change of Institution**.** If the applicant's mentor or co-mentor leaves their current position or institution, the applicant is required to identify a new mentor and submit updated documents. Please refer to post-submission materials accepted under Key Dates.
- Change in Proposal (Scope, Timeline, Budget, etc.). If the applicant makes significant changes to their submitted proposal—including modifications to the specific aims, research strategy, timeline, or budget—they must report these updates immediately. Should Conquer Cancer be notified of these changes after the applicant has been notified of an award, Conquer Cancer has the right in its sole discretion to withdraw the award.

Any changes to the institution, position, mentor, or project scope after an award notification will require the submission of additional documentation and are subject to review and approval by Conquer Cancer. Conquer Cancer has the right in its sole discretion to withdraw the award if these changes are not approved.

Award Notification

Applicants can expect to be notified in April 2027 via email from awards@mail.asco.org. To ensure receipt of notifications from the application portal, it is highly recommended to include awards@mail.asco.org to the applicant's safe sender list. All communication regarding applications, including award notifications, will be sent to the preferred email address on the applicant's membership profile. For questions, please contact grants@conquer.org.

Application Procedures

All applications must be submitted in accordance with the requirements and instructions of this RFP. All application materials must be in English and must be submitted online through the Conquer Cancer application portal at awards.asco.org. No paper applications sent by mail, e-mail, or fax will be accepted.

Applicants are encouraged to start their application early due to the complexity of the online application process. The full application must be submitted by **11:59 PM ET on January 28, 2027.** No late applications will be accepted. Please note that technical assistance is only available until 5:00 PM ET on January 28, 2027.

Helpful tips for using the application portal are included in Appendix B.

1. **Applicant Information (required).** This section includes the following:
   - Applicant Information. This information is pulled directly from the applicant's ASCO membership profile. If changes need to be made to the applicant's information, visit profile.asco.org. Make sure that the applicant's profile has the most up-to-date information before beginning an application. Changes made to the applicant's profile are not saved in real-time but will be reflected on this form before submitting the full application.
     - First Name
     - Middle Name
     - Last Name
     - Degree
     - Primary Organization Name
     - Address (including city, state, and zip code)
     - Country
     - Primary email address (all future communications about the application will be sent to this address)
     - ORCID ID
     - ASCO Member ID
   - Additional questions and required information. Answer the following:
     - Do you have a medical degree or international equivalent?
     - Do you have a full-time faculty appointment (this includes full-time instructor position)?
     - Academic Rank: Select from the drop-down list.
     - Certification/Subspecialty Training: Select from the drop-down list.
     - Field of Clinical Training: Select all that apply
     - Field of Research Training: Select all that apply.

   - After completing this form, click **"Mark as Complete"**.

2. **Project Information (required)**. This section includes the following proposed project information (all are required):
   - Research Project Title (250 characters maximum): Provide a short descriptive title of the research project.
   - Brief Research Project Description/Abstract (3000 characters maximum): Provide a brief abstract of the research project.
   - Lay Abstract (2500 characters maximum). Provide a layperson summary of the project. Describe the work in such a way that it can be understood by people who do not have scientific or medical backgrounds. Avoid using technical and scientific terms. Do not include confidential information. If selected to receive an award, Conquer Cancer may use the layperson summary on its website and/or other public facing materials.
   - Specific Aims (1000 characters maximum per aim): Select the number of aims from the drop-down list. Briefly describe the goals of each aim separately and concisely in the boxes provided. Include the following for each aim: the aim objective (e.g., to test a stated hypothesis, create a novel design, solve a specific problem, challenge an existing paradigm or clinical practice, address a critical barrier to progress in the field, or develop new technology), the research approach, and the expected outcomes. At least one specific aim is required. Details (e.g.,

background, rationale for each aim and alternative strategy) for respective aims can be included in the research strategy section.

- Subject Area: Select one Subject Area from the drop-down list that best describes the research project, its objectives and proposed project outcomes. If "Other" is selected, provide information in the text field.
- Focus Area(s): Select all that apply. If "Other" is selected, provide information in the text field.
- Topic: Select “Yes” or “No” in response to the question “Does your research project address health disparities and inequities?”
- Research Classification: Select a category that relates to the research project. The list has six broad categories of scientific interest in cancer research.
- Type of Research Study: Select the type from the drop-down list to indicate if the research project is "Clinical", "Pre-clinical", or “Health Services Research”.
    - If “Clinical” is selected, indicate the clinical trial phase and clinical trial number or identifier.
- Assurances: IRB and IACUC approvals are not required at the time of submission but highly encouraged to provide documentation.
    - Animal Use. Indicate whether animals will be used in the research. If yes, select the appropriate status.
        - If the status is Approved, enter the IACUC Approval Date, Expiration Date, and Number.
        - If the status is Exempt, enter the Exemption Number.
        - If the status is Pending, please indicate the anticipated date of approval and enter any additional comments in the comment box.
    - Human Subjects. Indicate whether human subjects will be involved in the research. If yes, select the appropriate status.
        - If the status is Approved, enter the IRB Approval Date, IRB Expiration Date, and Assurance Number.
        - If the status is Exempt, enter the Exemption Number.
        - If the status is Pending, please indicate the anticipated date of approval and enter any additional comments in the comment box.
- Use of Drug(s): Indicate if the research involves the use of drug(s). If yes, enter the name of the drug(s) and the drug manufacturer(s). It is **required** to include a letter from the manufacturer(s) or supplier(s) that they will provide the drug in the Letter of Support from Drug Company section of the application.
- Resubmission: Select “Yes” or “No” from the drop-down list to indicate if the application is a resubmission of a previous application.
- How many mentors do you have?
    - Select the number of mentors the applicant has (maximum of 2).
    - Indicate if the mentor is an ASCO member (if mentor is not an ASCO member, the applicant will be required to invite a Sponsor, who must be an ASCO member).
    - NOTE: It is important to enter the correct information, as it will create the Mentor and Sponsor Recommendation tasks in section 12. **The ‘Project Information’ form must be marked as complete to create the recommendation tasks.**

After completing this form, click **“Mark as Complete”**.

3. **Research Strategy (required).** The research strategy is limited to six (6) typewritten, single-spaced pages, with one-inch margins and using an 11-point Arial font. ALL pertinent tables, pictures, and graphs MUST be included within the 6-page limit. **If the uploaded document exceeds the page limit, Conquer Cancer will return the application.**

   The Research Strategy must contain the following information:

   i. Significance and Background
      A. Explain the importance of the problem or critical barrier to progress in the field that the proposed project addresses.
      B. Explain how the proposed project will improve scientific knowledge, technical capability, patient care, and/or critical practice in one or more broad fields.
      C. Describe how the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field will change if the proposed aims are achieved.
      D. Provide preliminary data, supporting methodologies, relevant findings in the field related to the project and describe the research gap to support the hypothesis.

   ii. Innovation
      A. Explain how the application challenges and seeks to shift current research, clinical practice paradigms, or patient care.
      B. Describe any novel theoretical concepts, approaches or methodologies, instrumentation or interventions to be developed or used, and any advantage over existing methodologies, instrumentation, or interventions.
      C. Explain any refinements, improvements, or new applications of established theoretical concepts, approaches or methodologies, instrumentation, or interventions.

   iii. Approach
      A. Describe the overall strategy, methodology, and analyses to be used to accomplish the specific aims of the project. Include how the data will be collected, analyzed, and interpreted as well as any resource sharing plans as appropriate. For clinical trials, briefly describe any inclusion and exclusion criteria, and their rationale.
      B. When patients are involved, the precautions to ensure patient safety and confidentiality, minimize patient burdens, and the relevance or implications for patient care should be explained.
      C. Describe any strategy and/or relevant data to establish feasibility and address the management of any high-risk aspects of the proposed work. Describe any facilities and resources that will be used to complete the study, including relevant industry support.
         - *Note:* Appropriate documentation (e.g. approvals, collaboration letters) must be uploaded in the Supporting Documentation section to assure a reviewer that the applicant's project is feasible in the timeframe of the grant.

iv. Anticipated Results and Alternative Strategies
   A. Describe the anticipated results and outcomes of the proposed aims, and potential next steps.
   B. Describe any benchmarks that will be used to determine success in the aims and anticipated outcomes.
   C. Discuss limitations in the experimental design, potential problems, and alternative strategies that will be employed if anticipated outcomes are not achieved.

Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

Use this file naming convention: *2027CDA_ResearchStrategy_your last name*

After completing this form, click **"Mark as Complete"**.

4. **Biostatistical Section (required). Applications will be reviewed and scored by a biostatistical reviewer for statistical rigor.** The applicant is required to closely work with the collaborating biostatistician and/or bioinformatician in developing the research strategy including the design of the experiments, data collection, analysis, and interpretation of the data.

Upload the following documents.

i. **Biostatistical Plan (required).** The detailed statistical plan must be typewritten, single-spaced with one-inch margins and 11-point Arial font. Any references for this section can be noted here and, included with the Cited References to comply with the page limit. **If the uploaded document exceeds the page limit, Conquer Cancer will return the application.**

   All studies whether clinical, observational, in-vivo or laboratory-based in vitro research proposals must include the primary objective/hypothesis, clearly defined endpoint of the study, description of experimental design and study groups that will be compared, justification of the proposed study sample size, detailed procedures for data analysis, and any other appropriate statistical details that describe the summary measures that will be used to meet the objectives of the study. An appropriate sample size justification should include all parameters and assumptions required for the computation of the sample size (including key references if novel methods used, and sufficient enough to allow replication): the effect size, power and type I error rates for each aim where applicable. If Bayesian approaches are used, prior assumptions and operating characteristics should be provided. When relevant to the project, the plan should state the median follow-up, prevalence of mutations in a given population, accrual rate, or number of events for a time-to-event outcome. The statistical analysis plan should provide details for analyzing high-throughput data including the pipelines and procedures, if the proposal involves such data. For studies using artificial intelligence and machine learning techniques, a detailed statistical design and analysis plan for algorithms, training data and validation data, performance metrics, and data/software sharing must be explained in the proposal demonstrating the rigor and validity of the study to draw meaningful conclusions. Connect the biostatistical plan to how AI is being leveraged in the study.

ii. **Letter(s) of Support (required).** The letter from the collaborating biostatistician and/or bioinformatician should clearly state a mentoring plan including the roles and responsibilities of the biostatistician, the support provided with the study design, clinical trials, data analysis, interpretation of findings, and the resources available to ensure statistical rigor and feasibility of the proposed project. There are no specific background requirements for biostatisticians as long as they have the expertise needed to support the biostatistical aspect of the proposed research project. Graduate students will not be allowed as biostatical collaborators for CDA grant applications.

Visit the Application Resources on asco.org. It includes a webinar recording on "Working with a Biostatistician."

Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

Use this file naming convention:
2027CDA_BiostatisticalPlan_your last name
2027CDA_LOS_your last name

After completing this form, click **"Mark as Complete"**.

5. **Cited References (required).** Upload a bibliography of any references cited in the Research Strategy. The Cited References has no page limit, must be typewritten with single-space, one-inch margins and an 11-point Arial font.

   Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

   Use this file naming convention: *2027CDA_Cited References_your last name*

   After completing this form, click **"Mark as Complete"**.

6. **Patient Impact Section (required). Applications will be reviewed and scored by a patient advocate.** This section must describe the impact of the study on patients and the role of the patient advocate in the project. The patient advocate reviewer will use this section, among other materials, to assess how well the applicant explains how the proposed project could impact patients, and how the project would address the needs of cancer patients.

   The patient advocate should be involved early during the project's development and the application planning. This ensures that the research is relevant to patients, minimizes patient burdens, and effectively addresses patient needs. A patient advocate can be a cancer survivor, a person living with cancer, a family member, a primary caregiver of a person living with cancer, or any individual with a strong personal connection to cancer. A patient advocate must have a dedicated interest in cancer

research and survivorship, with the ability to represent the patient/survivor/co-survivor perspective during the development and conduct of the project.

Clinical proposals must be developed with a patient advocate. Clinical studies must be clearly written, well-designed, and must follow all ethical and Institutional Review Board regulations. Clinical studies must clearly demonstrate how they will lead to future clinical research and directly benefit patients. Applicants are encouraged to work with their mentors to leverage institutional resources, such as community advisory groups or advocacy programs. Applicants are also encouraged to contact local cancer advocacy groups when appropriate. Whenever possible, applicants are strongly recommended to partner with an advocate who has experience with the specific cancer type being studied.

Note: If your institution does not have patient advocates to help in developing your study, please visit the Application Resources on asco.org. It includes a webinar recording on "Working with a Patient Advocate", and article on "Patient Engagement in Cancer Research From the Patient's Perspective" and resources for locating patient advocates involved in cancer research.

The applicant and patient advocate should work together to:

- Assess Patient Relevance: Discuss the project to identify its potential translational and clinical significance from the patient perspective, outlining how success will lay the groundwork for future translational and clinical research studies.
- Evaluate Family and Caregiver Impact: Discuss how the project will influence fundamental concepts in cancer research that directly benefit to patients, their families, their and caregivers
- Review Project Design: Discuss and refine the overall research and clinical design of the project.
- Co-author the Lay Abstract: Work together to develop the Lay Abstract in the project information section.

Upload the following documents:

i. **Patient Impact Questions (required, template provided).** This document informs reviewers the project's relevance to patients and details the specific contributions of your patient advocate. Complete the provided template using clear, lay-friendly language. Limit responses to no more than 2500 characters per question.
ii. **Letter of Support from the Collaborating Patient Advocate (required).** This letter validates the partnership and commitment of your patient advocate. It must outline both the scope of the patient advocate's involvement to date and their expected role in proposed research moving forward.

Upload as PDF files. Click "**Attach File**" and select the file to be uploaded in the application.

Use this file naming convention*:*
2027CDA_PA_template_your last name
2027CDA_PA_LOS_your last name

After completing this form, click **"Mark as Complete"**.

7. **Budget (required).** The award funds will be directed to the Sponsoring Institution and must be used for the pursuit of the applicant's research project, including salary support, supplies, equipment, travel, etc. The budget must be entered directly into the budget form of the online application. Provide a budget justification for the entire project period in the "Description of Costs" column. If specific budget categories will be covered by other sources, provide details in the "Description of Costs" to ensure feasibility of the proposed project and availability of support. The direct and indirect costs will automatically calculate at the bottom of the form as you enter your figures. **Do not use a comma when entering budget amounts.**

   Budget Guidelines:
   - Total Award: The total award amount is $200,000 payable in annual increments of $66,666 over three years. **The total cost requested per year should not exceed $66,667. The total budget requested must be exactly $200,000.** During the award period, at least 80% of the current reporting year's budget must be expended by the end of that year to receive the next annual payment installment.
   - Research support: At least $59,966 per year must support costs directly related to the research project such as personnel salary, supplies, equipment, and other expenses. Budgeted items must align with available institutional facilities and resources. Patient care costs that are reimbursable by a third-party payor, professional membership dues (including ASCO), tuition fees, and other fees for academic courses and certifications are unallowable costs. Salary limits will follow the NIH salary cap.
   - Travel: Up to $2,500 per year may be allotted for travel to the ASCO Annual Meeting and other travel essential to conducting the study. Attendance is **mandatory** at the Conquer Cancer Grants and Awards Ceremony, which will take place during the ASCO Annual Meeting on June 4, 2027. As the award term begins after the Grants and Awards Ceremony, Conquer Cancer approves costs incurred to attend the Ceremony as allowable pre-award costs.
   - Indirect costs: Up to $4,200 per year (or 6.3% of the yearly total award amount) may be applied to the sponsoring institution's overhead or facilities and administrative costs.

   After completing this form, click **"Mark as Complete"**.

8. **Project Timeline Form (required).** Enter each major project milestone/activity, a brief description, the expected completion date, the status and if it is an associated deliverable **using the required template** . A deliverable is something that can be included in a progress report, such as a publication or an approval letter. The applicant is not required to have deliverables during the award term. However, to ensure the feasibility of the study, the timeline should be clear what outcomes will be achieved during the award period and its expected timeframe. The expected date of completion for the major milestones described in each aim of the proposal must be provided.

   Ensure all columns and rows in the completed template are visible on each page and set to proper print area. Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

Use this file naming convention: *2027CDA_Timeline_your last name*

After completing this form, click **"Mark as Complete"**.

9. **Resubmission Documentation (required for resubmissions only).** Applicants resubmitting a previous application are **required** to upload a one-page introduction addressing the feedback and critiques received during the previous application cycle.

   The introduction is limited to one (1) typewritten, single-spaced page with one-inch margins and 11-point Arial font. This introduction must clearly outline how the application has been modified in response to the previous review comments. It is advised that applicants ask their mentors to read the reviewers' critiques and the resubmission responses to confirm that the critique has been considered and appropriately addressed.

   Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

   Use this file naming convention: *2027CDA_Resubmission_your last name.*

   After completing this form, click **"Mark as Complete"**.

10. **Personal Statement Form (required)**. Enter answers to the following questions. Each response must not exceed 2,000 characters.
    - Career plan and impact of award. Provide a brief description of the applicant's career plan and explain how receiving this award would impact the applicant's career.
    - Percentage time of research activities. Provide the percentage of time the applicant will spend on total research activities during the award period.
    - Applicant's role. Briefly describe the applicant's role versus the mentor's role in the proposed research study. Briefly describe who will collect and analyze the data.
    - Salary support. List the applicant's sources of salary support during the award period.
    - YIA project accomplishments. If the applicant was previously awarded a Conquer Cancer Young Investigator Award (YIA) and the proposed CDA project is a continuation of the study, briefly describe the key accomplishments of the YIA project. If the applicant is not a previous Conquer Cancer YIA recipient, please indicate N/A.
    - Other funding sources. List other funding agencies/organization where this research proposal was or will be submitted. If none, please indicate N/A.

    After completing this form, click **"Mark as Complete"**.

11. **Applicant's Biosketch (required)**. Applicants can use either the latest NIH biosketch template (must not exceed five (5) pages) or a single digitally certified PDF biosketch generated directly in SciENcv (if available). The SciENcv biosketch has no page limit.

    Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

Use this file naming convention: *2027CDA_Biosketch_your last name*

After completing this form, click **"Mark as Complete"**.

12. Mentor and Sponsor Recommendation (required).

- Before working on this section, please indicate the number of mentors in the 'Project Information' section and click '**Mark as Complete**'.
- At least one of the applicant's mentors must be from the applicant's sponsoring institution. For questions about selecting a mentor, contact grants@conquer.org.
- If the application indicates that the mentor(s) is/are not an ASCO member, a Sponsor Invite appears in the left navigation. The sponsor must be an ASCO member from the applicant's sponsoring institution and is only required when the mentor is not an ASCO member. **If the applicant has two mentors and one mentor is an ASCO member, a sponsor is not required.**
- **To request a recommendation from the mentor or sponsor:**
    - Click "**Request a Recommendation**".
    - Enter the First name, Last name, Email address, and a brief message (optional) to the mentor or sponsor.
        - **IMPORTANT**: If the mentor is an ASCO member, make sure to enter the email address associated with the mentor's ASCO user account, otherwise this recommendation will not be available to the mentor when they log in to the system. If an incorrect email address is used, withdraw the request and create a new request using the correct email address.
    - Click "**Send Request**".
    - The mentor will receive an email with an invite to complete a recommendation in the application portal. This includes submitting their Biosketch and Letter of Support for the applicant.
    - If a sponsor was invited, the sponsor will receive an email with an invite to complete a recommendation in the Application Portal. This includes submitting their Biosketch and Letter of Support for the applicant.
    - After logging in the system, the mentor and sponsor must click "**Start**" and then '**Accept**' or '**Decline**' the recommendation request from the applicant. Upon accepting, the mentor and sponsor will be able to complete and submit their recommendation.
    - The applicant will be notified by email when the mentor or sponsor Accepts or Declines the recommendation.

Mentor must submit the following:

- Mentor's Biosketch. The mentor can use either the latest NIH biosketch template (must not exceed five (5) pages) or a single digitally certified PDF biosketch generated directly in SciENcv (if available). The SciENcv biosketch has no page limit.
- Letter of Support. The letter must be signed, written on institutional letterhead and should include the following information:

  - Confirmation that the applicant is within the first four years of a full-time faculty appointment at the time of grant submission
  - A critical review of both the applicant and the research proposal
  - The role of the applicant in the development of the proposal
  - The role(s) or anticipated role(s) the applicant holds (will hold) at the institution
  - The level of institutional commitment to the applicant's career development as an independent clinical investigator
  - Assurance that the applicant's sponsoring institution will provide adequate facilities and support for performance of the proposed work
- If there is more than one mentor, a biosketch and a letter of support is required from each mentor. ***Applicants should not have more than two mentors.***
- A mentor is strongly encouraged to have no more than two mentees applying for the Young Investigator Award, Global Oncology Young Investigator Award, and/or Career Development Award for this funding cycle.

The Applicant will be notified when the mentor submits a recommendation. The mentor must click "**Submit**" at the bottom of the page to trigger the email. The applicant will not be able to view the documents submitted by the mentor.


If there is a Sponsor, the Sponsor must submit the following:

- Sponsor's Biosketch. The Sponsor can use either the latest NIH biosketch template (must not exceed five (5) pages) or a single digitally certified PDF biosketch generated directly in SciENcv (if available). The SciENcv biosketch has no page limit.
- Letter of Support. The letter must be signed, written on institutional letterhead and should include the following information:
  - Confirmation that the applicant is within the first four years of a full-time, faculty appointment at the time of grant submission
  - A critical review of both the applicant and the research proposal
  - The role(s) or anticipated role(s) the applicant holds (will hold) at the institution
  - The level of institutional commitment to the applicant's career development as an independent clinical investigator
  - Assurance that the applicant's sponsoring institution will provide adequate facilities and support for performance of the proposed work

The Applicant will be notified when the sponsor submits a recommendation. The sponsor must click "**Submit**" at the bottom of the page to trigger the email. The applicant will not be able to view the documents submitted by the sponsor.

Resending or Withdrawing a recommendation request:

- Click the ellipsis (…) near the mentor's name and email and select the appropriate option from the drop-down list as shown below.



IMPORTANT: The mentor and sponsor must complete their task and click "Submit" prior to the application deadline. The applicant will be notified when the mentor and sponsor submit a recommendation. The applicant will not be able to submit the application until these tasks are submitted. Once the mentor and sponsor have submitted their documents, return to this task and click **"Mark as Complete"**.

13. **Mentorship Plan (required).** The mentorship plan must be **jointly written and signed** by the applicant and mentor(s) (including both mentors, if applicable). It is strictly limited to two (2) typewritten, single-spaced pages with one-inch margins and an 11-point Arial font; documents exceeding this limit will be returned by Conquer Cancer. To ensure continuous progress, the plan must outline a systematic professional development strategy. This includes detailing the structure of mentor/mentee interactions, explaining how the mentor will guide the applicant in aligning their aims with the proposed study or clinical trial, and identifying key career development activities (such as coursework, biostatistical training, journal clubs, grant writing, and manuscript preparation) required to build a successful career in clinical oncology research.

    Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

    Use this file naming convention: *2027CDA_MentorshipPlan_your last name*

    After completing this form, click **"Mark as Complete"**.

14. **Institutional Letter of Support from Department Chair or Dean (required).** A letter from the Department Chair or Dean from the applicant's sponsoring institution where the research project will be conducted must be provided. This letter must include a statement of institutional support and commitment confirming that the institution will provide the resources necessary to perform the

proposed research and that the applicant will have at least 50% protected time for research during the award period. This letter must be signed and on official letterhead. **If the letter is not signed and on official letterhead, Conquer Cancer will return the application.**

NOTE: If the mentor is the Department Chair, the institutional letter of support must come from the Division Head, Dean, or any member of the institution's leadership that can assure support on the performance of the proposed research. The sponsor may be the same individual writing the institutional letter of support, however, the sponsor letter of support should be written differently using the guidelines in #12.

Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

Use this file naming convention: *2027CDA_InstitutionalLOS_your last name.*

After completing this form, click **"Mark as Complete"**.

15. **Clinical Protocol (required).** For clinical studies or projects including specific aims as a part of a clinical trial, it is **required** to upload the clinical protocol.

    Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

    Use this file naming convention: *2027CDA_ClinicalProtocol_your last name*

    After completing this form, click **"Mark as Complete"**.

16. **Letter from Drug Company (required).** If the research project involves using a drug from a pharmaceutical company to perform the clinical trial/clinical study, it is required to submit a letter from the company to show support for the drug supply.

    Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application.

    Use this file naming convention: *2027CDA_DrugLOS_your last name*

    After completing this form, click "**Mark as Complete**".

17. **Publications (optional).** Up to two prior publications that are relevant to the proposed project may be included. The publications must highlight the applicant's experience and qualifications to conduct the proposed project. The applicant must be a co-author on these publications.

    To enter publications:
    - Select the total number of publications from the drop-down (1 or 2).
    - For each publication, enter the title, PubMed ID number, year, type, name, status, URL, and funding status.

- Upload as a PDF file. Click "**Attach File**" and select the file(s) to be uploaded in the application.

  Use this file naming convention: *2027CDA_Publication 1_your last name*

After completing this form, click **"Mark as Complete"**.

18. **Additional Supporting Documentation (optional).** This section may be used to upload any necessary additional information to support the application (e.g., additional preliminary data, letters documenting the feasibility of the project, a letter of collaboration from another laboratory providing expertise for this project, a letter of support for a collaboration, etc.). **All letters must be signed and on official letterhead.**

    Upload as a PDF file. Click "**Attach File**" and select the file to be uploaded in the application. Repeat this step to upload multiple files.

    Use this file naming convention for each document: *2027CDA_SupportingDoc1_your last name*

    After completing this form, click **"Mark as Complete"**.

19. **Institution Approval (required).** The Authorized Official representing the sponsoring institution must approve the completed application (both the project proposal and the budget) before submission by completing the "Institution Approval" task. This individual is typically from the institution's Office of Sponsored Research.

    - To request a recommendation from the Institution Approver:
      - Click "**Request a Recommendation**".
      - Enter the First name, Last name, Email address, and write a message (optional) to the Institution Approver.
      - Click "**Send Request**". The Institution Approver will receive an email notification with the message.
      - If the Institution Approver accepts or decline the recommendation request, the applicant will receive an email notification.
    - To resend or withdraw the request, click the ellipsis **(…)** near the Institution Approver's name and email and select the appropriate option from the drop-down list.
    - **IMPORTANT:** The Institution Approver must complete their task and click "**Submit**" at the bottom of the page **prior** to the deadline. An email notification will be sent to the applicant confirming that the task has been completed.
    - The applicant will not be able to submit the application until this task is submitted.
    - Once the Institution Approver has submitted the task, return to this section and click **"Mark as Complete"**.

20. **Review and Submit (required)**. The applicant will not be able to navigate to this page until all required sections have been "**Marked as Complete**" and all tasks from the Mentor(s), Sponsor (if applicable), and Institution Approver have been submitted.

    On the left navigation, click **"Review"** to review or **"Submit"** to submit the application.

    To download a copy of the application, click "**My Applications**". Click the ellipsis **(…)** on the specific application and click "**Download**".

    On the next screen, select the desired options and click "**Download**".

    A new tab will open. Once the download is ready, click "**Download**". The application will be downloaded as a zip file.

Appendix A. Terms & Conditions

Each applicant selected to receive a CDA, and their Sponsoring Institution, must execute a separate Terms and Conditions document with Conquer Cancer in order receive a CDA. This section of the RFP sets forth selected provisions of the Terms and Conditions that applicants and their Sponsoring Institution should review carefully before submitting an application for a CDA. This RFP does not contain the complete Terms and Conditions document. Conquer Cancer reserves the right to modify any of the provisions of the Terms and Conditions prior to execution by the applicant and Sponsoring Institution.

Certifications, Representations, Warranties, and Covenants

(1) Recipient and Sponsoring Institution each certify that to the best of their or its knowledge, the information provided in their Award grant proposal is complete and true. Recipient and Sponsoring Institution each agree to promptly notify Conquer Cancer of any changes to the information provided in the grant proposal or the award acceptance process including, but not limited to, information regarding whether the Recipient is a "Government Official" as defined therein.

Award Period

(2) The Recipient will not be absent from participation in the Research Project or from the Sponsoring Institution for extended periods of time during the Award Period, such as for a sabbatical leave or leave of absence, without prior written approval from Conquer Cancer. The Recipient may request that the Award Period be delayed with a start date that begins up to six months after the published start date indicated in the Request for Proposals, which request will be approved or disapproved by Conquer Cancer in its sole discretion.

Responsible Conduct of Research

(3) The Research Project will be conducted according to the highest scientific and ethical standards and in compliance with all applicable laws and regulations and with the policies of the Sponsoring Institution, including with respect to Sponsoring Institution's conflict of interest policies and procedures. To the extent policies of the Sponsoring Institution conflict with these Terms and Conditions, these Terms and Conditions will prevail.

(4) Upon request of Conquer Cancer, the Recipient will provide copies of documentation of Institutional Review Board approval for human research subjects to Conquer Cancer prior to commencing research on human subjects, if applicable.

(5) Upon request of Conquer Cancer, the Recipient will provide copies of documentation of Institutional Animal Care and Use Committee approval or international animal welfare board equivalent to Conquer Cancer prior to commencing research on animal subjects, if applicable.

Funds: Payment and Use

(6) The Award total is $200,000, paid in three annual installments of $66,666, on or about July 1, 2027, 2028, and 2029, subject to compliance by Recipient and Sponsoring Institution with these Terms and Conditions. The Award funds will be paid to the Sponsoring Institution.

(7) The Award will be used solely as detailed in the Research Project (including the grant proposal and budget).

(8) No more than 6.3% of total costs will be applied to overhead or indirect costs of the Sponsoring Institution in administering the Research Project. At least $59,966 per year of the Award funds will be applied to research support. No more than $2,500 per year will be used to cover the Recipient's travel expenses (including to the ASCO Annual Meeting). Direct costs include costs related to sub-grants and subcontracts. Salary limits will be equivalent to the NIH applicable limit. Conquer Cancer will not make payment of the next installment of Conquer Cancer Funds unless the Recipient expends at least 80% of their yearly budget by the end of the applicable reporting year, or the Recipient has submitted an explanation that is satisfactory to Conquer Cancer, in its sole discretion, as to why this requirement was not met.

(9) Award funds will not be used for expenditures incurred prior to the first day of the Award Period (except for expenses related to travel to the Conquer Cancer Grants and Awards Ceremony) or after the last day of the Award Period. No additional expenses may be paid from Award funds after Conquer Cancer has received the Recipient’s final expenditure report or after any unexpended funds have been returned to Conquer Cancer, which must be provided in accordance with specific paragraphs in the full Terms and Conditions.

(10) At the end of the Award Period, any unexpended funds and any funds expended inconsistent with the Research Project will be returned to Conquer Cancer.

(11) If the Research Project included budgeted subcontracts to other institutions, Recipient will be responsible for obtaining budget summaries and progress information annually, in concordance with the reporting schedule set forth herein. All consortium and contractual agreements will be subject to and will comply with these Terms and Conditions. Recipient will ensure that the Research Project is conducted in compliance with these Terms and Conditions.

(12) With prior written approval from Conquer Cancer, Recipient may subcontract with a third party even if not budgeted in the original research proposal. A request to reallocate the budget will be submitted to Conquer Cancer through Conquer Cancer’s application portal for approval and will include a description of the work to be performed by the third party, reason for contracting with the third party, and a complete budget for the third-party including revisions to the original budget categories. All contractual agreements will be subject to and will comply with these Terms and Conditions.

(13) Award funds not expended in the year for which they were budgeted may be carried over to the same budget component in the next year of the Award Period without prior approval of Conquer Cancer. However, a detailed justification of why funds were not expended and how they will be expended in the following year will be included in the expenditure report.

Requests for Budget Changes or Extensions

(14) The Recipient may move funds of up to 5% of the total yearly budget ($3,333) between budget categories or into new budget categories without prior written approval of Conquer Cancer. Notwithstanding the foregoing, budget limits on indirect and travel costs will be strictly followed and cannot be adjusted.

(15) Budget changes of greater than 5% per year between budget categories will be approved in writing by Conquer Cancer before expenditure of funds. The Recipient will submit a re-budget request with a detailed justification of the proposed change through the application portal.

(16) Any request for a no-cost extension or budget change must be made through the application portal no earlier than 90 days prior to the expiration of the Award Period. Requests received after the last day of the Award Period will not be accepted and will automatically be disapproved. No cost-extensions of up to six months may be approved by Conquer Cancer in its sole discretion. Conquer Cancer may approve up to a maximum of three no-cost extensions.

(17) Requests for a six month no-cost extension require a no-cost-extension request submission through the application portal and a detailed explanation of why the request is being made. Requests will only be approved if they pertain to Research Project. Conquer Cancer will approve or disapprove the request at its discretion.

(18) If a no-cost extension is granted by Conquer Cancer, the Recipient will submit additional progress reports and financial expenditure reports every six months during the extension term.

Change of Personnel

(19) Neither the Sponsoring Institution nor the Recipient is permitted to transfer the Award to a co-investigator or any member of the research team, or a mentor. The Recipient's mentor may not be changed without the prior written approval of Conquer Cancer. Conquer Cancer will approve or disapprove the request for mentor change at its discretion.

Changes in Research Focus and Project Scope

(20) Changes in the specific aims of the Research Project will not be allowed without prior written consent from Conquer Cancer. Any request for changes in the specific aims of the Research Project must be made through the application portal prior to performing any changes to the Research Project. Conquer Cancer will approve or disapprove the request at its discretion.

(21) Major changes in research design require prior written approval from Conquer Cancer. A request must be submitted by the Recipient through the application portal prior to performing any aspects of any newly designed study. Examples of a major change include, but are not limited to, studying a different patient population than originally proposed or studying a different therapeutic than originally proposed.

(22) Minor changes in research methodology are not subject to prior approval by Conquer Cancer, but must be explained and justified by the Recipient in the annual progress report.

Institution Transfer

(23) The Recipient must be affiliated or employed with the Sponsoring Institution throughout the Award period. If the Recipient accepts an appointment at another institution during the Award Period, and desires to have the Research Project transferred to the new institution, the Recipient will submit a request through the application portal to transfer the Award to the new institution at least 60 days before the anticipated date of transfer. Subject to Conquer Cancer's written approval and in Conquer Cancer's sole discretion, the Award may be transferred provided arrangements satisfactory to Conquer Cancer are implemented to continue the Research Project in a manner in which it was originally approved by Conquer Cancer. Any transfer must be approved in writing by Conquer Cancer before any such transfer takes place. Upon approval of a transfer of the Award to a new institution, the Sponsoring Institution will return any unexpended funds and any funds expended inconsistent with the Research Project to Conquer Cancer. The new institution will agree to comply with these Terms and Conditions. Conquer Cancer will make arrangements to provide remaining Award funds to the new institution.

(24) If the Recipient is unable or not permitted to transfer the grant to a new institution, the Recipient and the Sponsoring Institution will relinquish the Award and any unexpended funds and funds expended inconsistent with the Research Project will be returned to Conquer Cancer.

Program Reporting

(25) Throughout the Award Period, the Recipient will submit expenditure reports and progress reports regarding the Research Project through the application portal. It is the responsibility of the Recipient to submit the reports in a timely manner. Conquer Cancer may contact appropriate persons connected to the Research Project to ensure the progress reports and expenditure reports are received as required. Recipient and Sponsoring Institution will comply with the then-current procedures of Conquer Cancer regarding submission of progress and expenditure reports.

(26) Noncompliance with any of these Terms and Conditions, including failure to submit progress or expenditure reports, may result in the withholding of payment on this Award or other awards of Conquer Cancer in effect at the Sponsoring Institution, or on Conquer Cancer awards that may be awarded in the future, or such other action deemed appropriate by Conquer Cancer.

(27) Any unobligated balance must be returned in full to Conquer Cancer along with the final expenditure report. The check should be made payable to the "Conquer Cancer, the ASCO Foundation."

Post-Award Reporting Obligation

(28) The Recipient will respond to Conquer Cancer's requests for information on his/ her career progress following the Award Period and may be requested to provide their current Curriculum Vitae or update their information through the application portal using the "Career Progress" task. The information may be used for program evaluation and alumni communications. The Recipient understands that this obligation survives the Award Period and that they have an ongoing obligation to provide this information.

(29) Conquer Cancer reserves the right to include information relating to the Award in its periodic reports, annual reports, awardee directory, publicly accessible databases of privately funded grant awards, or in any other materials issued by or on behalf of Conquer Cancer or Conquer Cancer's affiliates.

Physician Payments Sunshine Act

(30) The Physician Payments Sunshine Act, or "Sunshine Act", is part of the Patient Protection and Affordable Care Act (health care reform) that passed in 2010.The law is designed to bring transparency to financial relationships between physicians, teaching hospitals, and healthcare companies. More information about the Sunshine Act can be found at https://www.asco.org/practice-policy/policy-issues-statements/asco-in-action/physician-payment-sunshine-act-additional. The Sunshine Act requires manufacturers of pharmaceutical drugs and devices, as well as group purchasing organizations, to report payments or transfers of value made to teaching hospitals and U.S. licensed physicians. (Please see the following excerpt from the Sunshine Act Final Rule that defines physician according to this law. If there are any questions regarding reportability, please talk with your institution. "As required by section 1128G(e)(11) of the Act, we proposed to define ''physician'' as having the meaning set forth in section 1861(r) of the Act, which includes doctors of medicine and osteopathy, dentists, podiatrists, optometrists, and chiropractors, who are legally authorized to practice by the State in which they practice.") Reports are made to the Centers for Medicare and Medicaid Services (CMS), a government agency. Conquer Cancer understands that payments made through the Conquer Cancer Career Development Award are reportable under the Sunshine Act as indirect payments or transfers of value because these awards are funded by companies that are considered manufacturers of pharmaceutical drugs and devices and/or group purchasing organizations. Conquer Cancer has entered into agreements with the supporters of the Conquer Cancer Career Development Award that require that Conquer Cancer provide reportable information under the Sunshine Act. Conquer Cancer's understanding is that payments made to the Recipient of the Conquer Cancer Career Development Award are reportable as research grants under the Sunshine Act.

(31) The Sunshine Act requires that all reportable payments or transfers made starting August 1, 2013 be reported to CMS. To assist Conquer Cancer in complying with its reporting obligations to its supporters, the Recipient agrees to provide information to Conquer Cancer, including: State of License; State License Number; National Provider Identifier (NPI) Number. Recipient must submit the information through the application portal by the due date specified.

(32) The information in this Terms and Conditions is not intended to provide legal advice to Recipient and Sponsoring Institution regarding the Sunshine Act. Recipient and Sponsoring institution should consult their own counsel with questions regarding the Sunshine Act.

Provision of Information to Funder

(33) The Recipient acknowledges, agrees, and consents to Conquer Cancer providing their current and future contact information to Funder.

(34) The Recipient acknowledges, agrees, and consents to Conquer Cancer providing lay summaries, progress and expenditure reports and copies of press releases relating to the Award or the Research Project to Funder.

Publications and Other Public Release of Results

(35) Conquer Cancer strongly encourages Recipient to submit the results of Research Project for publication or other public release. In the event the Recipient's results are published or otherwise publicly released either during or after the Award Period, the Recipient will provide Conquer Cancer with a copy of such publication or public release. All publications and public releases will include an acknowledgment of Conquer Cancer and Funder (see Public Announcements and Acknowledgment).

(36) Conquer Cancer supports the widest possible dissemination of funded research results. Recipient is highly encouraged to publish in scientific journals that will provide public access to the research findings no later than twelve months after the date of publication.

Public Announcements and Acknowledgments

(37) Conquer Cancer will announce the Award and other recipients of the Conquer Cancer Career Development Award. Conquer Cancer anticipates that the Sponsoring Institution may wish to make a public announcement of this Award. The Sponsoring Institution will submit to Conquer Cancer any proposed announcement, press release, or other public statement by the Sponsoring Institution relating to the Award, prior to release, and to coordinate the release of such public announcement, press release, or statement with Conquer Cancer. A copy of any press release, announcement, or public statement must be provided to Conquer Cancer.

(38) The Recipient and the Sponsoring Institution will acknowledge the support of the Conquer Cancer and Funder in all publications and presentations of the research funded by the Award.

The Recipient understands that all abstracts, publications, and presentations resulting from research supported by the Award will contain the acknowledgment, "This work was funded by a Conquer Cancer Career Development Award, supported by Funder. Any opinions, findings, and conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of the American Society of Clinical Oncology® or Conquer Cancer®, or the Funder."

(39) The Recipient is encouraged to use an emblem for the Conquer Cancer Career Development Award on posters, presentations, and similar items produced for scientific meetings and conferences. The emblem may be used with the acknowledgment language. The Recipient can request this emblem by sending an email to grants@conquer.org.

Intellectual Property Rights

(40) Conquer Cancer and Funder will have no intellectual property rights or other rights in or to data collected or scientific discoveries made through the Research Project funded by the Award. Conquer Cancer encourages its recipients and their sponsoring institutions to report to Conquer Cancer any inventions, discoveries, or intellectual properties that result from the support of the research.

Appendix B. Helpful Tips for Using the Application Portal

Getting Started

To access the application portal, go to **awards.asco.org**

- *If you have an existing ASCO account,* use your ASCO credentials to log into the application portal. If you are having issues logging in, click the "Need Help?" link in the "Log-in" page.
- *If you do not have an ASCO account,* go to awards.asco.org and click "**Log-in**" in the top right corner of the screen. On the next screen, click "**Create Account**" and follow the prompts to complete your account setup and create a password. After your account is set up, you will be returned to the application portal.
- *To initiate an application,* once logged into the application portal, click "**View Programs**", select the program "**Career Development Award**", and click "**Apply**".
- *NOTE:* Make sure that your ASCO membership profile has the most up-to-date information before beginning an application

Completing the Eligibility Quiz

You will first be asked to complete an eligibility quiz. Once you have answered each question, click "**Mark as Complete**" at the bottom of the page. You will then receive an email to confirm your eligibility. If you are eligible, you will automatically have access to the full application. The different application tasks will appear in the left navigation. If you have any questions regarding eligibility, contact grants@conquer.org.

Navigating the Application

- Click the task(s) on the left navigation to start working on your application.
- Click "**Save and Continue Editing**" at the bottom of the page as you go through the application.
- When finished with a particular task (e.g., Project Information), click "**Mark as Complete**" at the bottom of the page to validate task completion.
- If you need to edit a task after it has been Marked as Complete, click the ellipsis **(…)** on the top right corner of the task as shown below. Select "**Edit**" to reopen the form.
    - *IMPORTANT! Do NOT click "Reset" as this will delete previously entered data!*




Uploading a Document

- Click "**Show accepted formats**" to determine the file formats accepted. Documents should not be password protected.
- Documents must follow the file naming convention and requirements for page limits, margins, and fonts (see individual application sections for details). **If any document you uploaded does not meet the specific criteria, Conquer Cancer will return your application.**
- To upload a document, click "**Attach File**" and select the file to be uploaded.
- To edit a file name, click the ellipsis **(…)** next to the file name as shown below. Select "Edit" and enter the new file name based on the file naming convention.
- To remove or replace an uploaded document, click the ellipsis **(…)** next to the file name as shown below. Select "**Remove**" then click "**Attach File**".
- NOTE: You may need to clear your browser's cache to make sure you are able to view the re-uploaded document.



Requesting a Recommendation

- As part of your application process, you will need to "**Request a Recommendation**" from third parties such as a Mentor, Sponsor, and Institution Approver. Click on the task and fill in the details of the Recommender including the First Name, Last Name, Email, and a brief message (optional) to send the Recommender. Once the information is submitted, an automated email will be sent to the Recommender letting them know that they've been asked to provide a recommendation. When the recommendation is submitted, you will be instantly notified.
- If the Recommender didn't receive an email invite, confirm that you sent the invite to the correct email address and there are no spelling errors, ask the Recommender to check their junk/spam folder, or resend the Invitation.
- To resend or withdraw the request, click the ellipsis **(…)** near the Recommender's name and email and select the appropriate option from the drop-down list as shown below.



Receiving Notifications

Add awards@mail.asco.org and grants@conquer.org to your safe senders list to ensure timely receipt of notifications associated with recommender task submissions, application submissions, etc. If you are not receiving notifications, check your junk/spam folders first, then contact grants@conquer.org for additional assistance.

Appendix C. Application Information Use and Sharing

Conquer Cancer may use and process the information submitted through this application form for several purposes, including but not limited to: 1) evaluating the application, 2) communicating with you regarding your application and other opportunities that may be of interest to you, 3) publishing information regarding Conquer Cancer's grants and awards program, including through third party databases, 4) informing Conquer Cancer's grant making strategies and policies, and 5) for other legitimate purposes in keeping with Conquer Cancer's Privacy Policy and charitable mission. Information submitted through this application form will be kept on secure servers accessible to Conquer Cancer personnel and third parties authorized by Conquer Cancer to perform functions on Conquer Cancer's behalf.

In addition, by submitting an application form to Conquer Cancer, the applicant grants Conquer Cancer the right to use all application information submitted, outside of the research proposal, for any purpose.

The details of research proposals submitted are considered confidential property of the applicant. Conquer Cancer is permitted to share research proposals with Conquer Cancer staff and reviewers, third party contractors, and potential supporters, and Conquer Cancer will require all to maintain the confidentiality of such proposals.

If an applicant is selected for an award, the applicant grants Conquer Cancer permission to deposit grantee information collected in any documents or communications related to the application (including but not limited to investigator name, degree(s), clinical specialty, Open Researcher and Contributor ID

(ORCID), institution and institutional information, project title, abstract, grant start date and duration, and grant amount) into the Health Research Alliance (HRA) online database (HRA Analyzer) of privately funded grants, the Dimensions database, or any other similar database.

If an applicant is approved to receive funding but Conquer Cancer does not have funding available, the applicant grants Conquer Cancer permission to share the full proposal to potential supporters.

Appendix D. Physician Payments Sunshine Act

The Physician Payments Sunshine Act, or "Sunshine Act", is part of the Patient Protection and Affordable Care Act (health care reform) that passed in 2010.The law is designed to bring transparency to financial relationships between physicians, teaching hospitals, and healthcare companies. More information about the Sunshine Act can be found at https://www.asco.org/news-initiatives/policy-news-analysis/physician-payment-sunshine-act-additional-details-about-final.

The Sunshine Act requires manufacturers of pharmaceutical drugs and devices, as well as group purchasing organizations, to report payments or transfers of value made to teaching hospitals and U.S. licensed physicians. (Please see the following excerpt from the Sunshine Act Final Rule that defines physician according to this law. If there are any questions regarding reportability, please talk with your institution. "As required by section 1128G(e)(11) of the Act, we proposed to define ''physician'' as having the meaning set forth in section 1861(r) of the Act, which includes doctors of medicine and osteopathy, dentists, podiatrists, optometrists, and chiropractors, who are legally authorized to practice by the State in which they practice.") Reports are made to the Centers for Medicare and Medicaid Services (CMS), a government agency.

Conquer Cancer understands that payments made through this award are reportable under the Sunshine Act as indirect payments or transfers of value because these awards are funded by companies that are considered manufacturers of pharmaceutical drugs and devices and/or group purchasing organizations.

Conquer Cancer has entered into agreements with the supporters of this award that require that Conquer Cancer provide reportable information under the Sunshine Act. **RECIPIENTS OF YOUNG INVESTIGATOR AWARDS MAY BE REPORTED ON THE CMS OPEN PAYMENTS WEBSITE AS HAVING RECEIVED PAYMENTS OR TRANSFERS OF VALUE FROM MANUFACTURERS OF PHARMACEUTICAL DRUGS AND/OR DEVICES.** If there are any questions about reporting due to the Sunshine Act, please contact Conquer Cancer at 571-483-1700 or operations@conquer.org.

Disclaimer: The information on this section is not intended to provide legal advice. For legal advice concerning the Sunshine Act, the applicant must consult their institution or legal counsel.

For more information, see Terms and Conditions located in Appendix A.

Appendix E. Compliance with Applicable Legal Requirements (For Non-U.S. Institutions and Entities)

The award of the CDA is subject to applicable financial and legal requirements, including but not limited to applicable laws addressing foreign corrupt practices and economic and trade sanctions and embargoes (including but not limited to those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury and the U.S. Department of Justice). Notwithstanding any other provision in this this Request for Proposals, any grant award is contingent on Conquer Cancer's ability to transfer grant funds to the sponsoring institution and/or individual(s) and support the research project to be conducted by the applicant in compliance with all applicable legal requirements. Conquer Cancer will not accept applications from, and/or make grant awards to, certain foreign sponsoring institutions or individuals if Conquer Cancer is prohibited from doing so under U.S. sanctions laws, or if Conquer Cancer would be required to obtain a license from the Office of Foreign Assets Control or the Department of Commerce to make such grants. If it is impossible or inadvisable for Conquer Cancer, in its sole and absolute discretion, to fulfill its obligations in a grant award, including but not limited to the transfer of grant funds to the sponsoring institution and/or individual(s) pursuant to applicable legal requirements, the grant will not be awarded to the sponsoring institution and/or individual. If, after payment of the first installment of a grant award, it becomes impossible or inadvisable for Conquer Cancer, in its sole and absolute discretion, to transfer grant funds to the sponsoring institution and/or individual(s) pursuant to applicable legal requirements, then Conquer Cancer shall have no obligation to pay additional installments of the grant award. It is the responsibility of the sponsoring institution and the applicant to provide Conquer Cancer with the information or lawful means that permit Conquer Cancer to transfer the grant funds in compliance with all legal requirements.

Among the resources available to evaluate compliance with requirements administered by the Office of Foreign Assets Control are:

- http://www.treasury.gov/resource-center/sanctions/Pages/default.aspx
- http://www.treasury.gov/resource-center/sanctions/Programs/Pages/Programs.aspx
- http://www.treasury.gov/resource-center/sanctions/SDN-List/Pages/default.aspx